Cite
HARVARD Citation
Au, H. et al. (2013). Health‐Related Quality of Life With Adjuvant Docetaxel‐ and Trastuzumab‐Based Regimens in Patients with Node‐Positive and High‐Risk Node‐Negative, HER2‐Positive Early Breast Cancer: Results from the BCIRG 006 Study. Oncologist. pp. 812-818. [Online].